Quarterly ResultAug 13, 2026, 04:06 PM
Invivyd Q2 Revenue $14.3M; DECLARATION & LIBERTY Trials Complete
AI Summary
Invivyd reported Q2 2026 PEMGARDA net product revenue of $14.3 million, a 21% increase year-over-year. The company announced the completion of enrollment for its DECLARATION pivotal clinical trial and LIBERTY clinical trial, with top-line data for both expected in late Q3 2026. Cash and cash equivalents stood at $160.1 million, projected to fund operations through the DECLARATION data readout. However, the company's net loss widened to $44.4 million due to increased R&D and SG&A expenses, and it received notice of PEMGARDA's EUA termination effective June 29, 2027.
Key Highlights
- Q2 2026 PEMGARDA net product revenue was $14.3 million, up 21% from Q2 2025.
- DECLARATION pivotal clinical trial enrollment is complete, with top-line data anticipated in late Q3 2026.
- LIBERTY study fully dosed, with top-line data anticipated in late Q3 2026.
- Cash and cash equivalents were $160.1 million as of June 30, 2026.
- R&D expenses increased to $29.4 million in Q2 2026 from $9.6 million in Q2 2025.
- SG&A expenses increased to $29.5 million in Q2 2026 from $16.6 million in Q2 2025.
- Net loss for Q2 2026 was $44.4 million, compared to $14.7 million in Q2 2025.
- Invivyd received 12 months' advanced notice of EUA termination for PEMGARDA in July 2026.
Price Impact
More from IVVD